2NXD image
Deposition Date 2006-11-17
Release Date 2007-09-18
Last Version Date 2023-08-30
Entry Detail
PDB ID:
2NXD
Title:
Structure of HIV-1 protease D25N complexed with rt-rh analogue peptide GLY-ALA-ASP-ILE-PHE*TYR-LEU-ASP-GLY-ALA
Biological Source:
Source Organism:
HIV-1 M:B_ARV2/SF2 (Taxon ID: 11685)
(Taxon ID: )
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.25
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:PROTEASE RETROPEPSIN
Mutations:Q7K, D25N, L63P
Chain IDs:A, B
Chain Length:99
Number of Molecules:2
Biological Source:HIV-1 M:B_ARV2/SF2
Polymer Type:polypeptide(L)
Molecule:Analogue of RT-RH pol protease substrate peptide
Mutations:EP3D/TP2I//VP2'L
Chain IDs:C (auth: P)
Chain Length:10
Number of Molecules:1
Biological Source:
Primary Citation
Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease
Proteins 70 678 694 (2007)
PMID: 17729291 DOI: 10.1002/prot.21514

Abstact

Drug resistance in HIV-1 protease, a barrier to effective treatment, is generally caused by mutations in the enzyme that disrupt inhibitor binding but still allow for substrate processing. Structural studies with mutant, inactive enzyme, have provided detailed information regarding how the substrates bind to the protease yet avoid resistance mutations; insights obtained inform the development of next generation therapeutics. Although structures have been obtained of complexes between substrate peptide and inactivated (D25N) protease, thermodynamic studies of peptide binding have been challenging due to low affinity. Peptides that bind tighter to the inactivated protease than the natural substrates would be valuable for thermodynamic studies as well as to explore whether the structural envelope observed for substrate peptides is a function of weak binding. Here, two computational methods-namely, charge optimization and protein design-were applied to identify peptide sequences predicted to have higher binding affinity to the inactivated protease, starting from an RT-RH derived substrate peptide. Of the candidate designed peptides, three were tested for binding with isothermal titration calorimetry, with one, containing a single threonine to valine substitution, measured to have more than a 10-fold improvement over the tightest binding natural substrate. Crystal structures were also obtained for the same three designed peptide complexes; they show good agreement with computational prediction. Thermodynamic studies show that binding is entropically driven, more so for designed affinity enhanced variants than for the starting substrate. Structural studies show strong similarities between natural and tighter-binding designed peptide complexes, which may have implications in understanding the molecular mechanisms of drug resistance in HIV-1 protease.

Legend

Protein

Chemical

Disease

Primary Citation of related structures